Company Overview and News

 
Business leaders tackle federalism in forum

2018-08-28 bworldonline
By Arjay L. Balinbin, Reporter BUSINESSMEN on Tuesday raised concerns on the proposed shift to a federal form of government and the tax system under the draft Charter crafted by the Consultative Committee (ConCom) to Review the 1987 Constitution.
PPSTF PIP

 
Whole-of-nation

2018-08-13 bworldonline
WHEN government and society come together to address a national problem, the “whole-of-nation” principle is at work. It epitomizes national unity, solidarity, and teamwork. This is what Rotary Club of Manila’s (RCM) “One Rotary, One Philippines, One for Marawi” attempts to do — harnessing private sector companies and civic groups to partner with government agencies to address humanitarian assistance needs of people impacted by armed conflict and natural disasters.
PPSTF PIP

1
Finding success in Filipino endearment

2018-07-27 bworldonline - 1
“The kind of success I’m looking for is when someone says ‘Pepsi’, it comes with a bright smile,” said Pepsi-Cola Products Philippines Inc. (PCPPI) Independent Director Rafael Moreno Alunan III.
PPSTF PIP

 
Alunan: The success of Pepsi Philippines is in Filipino endearment

2018-07-25 business.inquirer.net
“The kind of success I’m looking for is when someone says ‘Pepsi’, it comes with a bright smile,” said Pepsi-Cola Products Philippines Inc. (PCPPI) Independent Director Rafael Moreno Alunan III.
PPSTF PIP

 
DOH post-graduate interns and Pepsi-Cola Products PH give free medical services in Batad, Iloilo

2018-06-26 business.inquirer.net
With the purpose of providing healthcare to the underserved communities of Batad Iloilo, post-graduate interns of the Department of Health Philippine Centers for Specialized Health Care internship program partnered with Pepsi-Cola Products Philippines Inc. (PCPPI) to host a two-day medical mission in the municipality.
PPSTF PIP

 
PDRF, PCPPI to provide 20,000-liter Water tanks for Marawi rehabilitation

2018-06-24 business.inquirer.net
Marawi is on its way to recovery. As the efforts continue to revive Lanao Del Sur’s capital after being ravaged by war, private institutions and government organizations are partnering to address the need for water of Maranaos and others in the area.
PPSTF PIP

 
Candidates from Mindanao dominate Miss Earth PH prelims

2018-05-09 lifestyle.inquirer.net
Gold medal winner Berjayneth Chee (center) of Balingasag is photographed with (from left) contest judge Monique Castro from Pepsi-Cola Products Philippines, third place finisher Halimatu Yushawu from Titay, and Silvia Celeste Cortesi from Rome, Italy. INQUIRER photo / Armin P. Adina
PPSTF PIP

 
Pepsi PHL seeks permission to sell HFCS inventory to AAC

2018-04-10 bworldonline
BEVERAGE manufacturers Asian Alcohol Corp. (AAC) and Pepsi-Cola Products Philippines, Inc. (PCPPI) have asked the Sugar Regulatory Administration to authorize AAC the use of PCPPI’s remaining high fructose corn syrup (HFCS) inventory.
PPSTF PIP

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...